Aktienanalyse zu Moolec Science SA (MLEC)MLECMoolec Science SA

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.